Skip to main content

Day: May 7, 2020

Ársreikningur Hafnarfjarðarbæjar 2019

Rekstrarafgangur ársins 2019 fyrir A og B hluta bæjarsjóðs nam 1.236 milljónum króna en áætlun ársins með viðaukum gerði ráð fyrir 642 milljóna króna afgangi. Rekstrarniðurstaða ársins fyrir A hluta var jákvæð um 426 milljónir króna en áætlun gerði ráð fyrir 45 milljóna króna halla.Mismun á áætlun og niðurstöðu má einkum rekja til þess að gjaldfærsla lífeyrissjóðsskuldbindingar var um 392 milljónum krónum lægri en gert hafði verið ráð fyrir. Fjármagnsliðir voru einnig um 245 milljónum krónum lægri en áætlun gerði ráð fyrir vegna lægri verðbótaþáttar. Veltufé frá rekstri nam 3.396 milljónum króna eða 11,9% af heildartekjum.„Við höfum stigið varfærin og ábyrg skref í rekstri sveitarfélagsins. Niðurstöður ársreiknings 2019 eru í takti við áætlanir okkar og samræmist markmiðum um ábyrga fjármálastjórn og vel ígrundaðar ákvarðanir,“ segir...

Continue reading

Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions

Hørsholm, Denmark, 7 May 2020 – Oncology Venture A/S (“OV” or the “Company”) today announces the issue of 1,952,475 new shares in connection with debt conversions.The Company has, based on a Board resolution from 6 May 2020, issued 1,952,475 new shares in connection with two debt conversions:Debt conversion of SEK 2,500,000 equivalent to 1,412,429 shares issued to Global Corporate Finance in connection with the Share Subscription Agreement announced on 6 May 2020, andDebt conversion of DKK 650,000 equivalent to 540,046 shares issued to a consultant for assistance in connection the establishment of 2X Oncology Inc.            The new shares hold no special rights.The subscription will be made at a subscription rate of SEK 1.77 per share of nominal DKK 0.05.The share capital is after the conversion a total of DKK 6,630,927.70 divided into...

Continue reading

Atlantica Reports First Quarter 2020 Financial Results

Net loss for the quarter attributable to the Company was $40.5 million, compared with a net loss of $9.0 million in the first quarter of 2019.Adjusted EBITDA including unconsolidated affiliates1 was $166.0 million, representing an 8.4% year-over-year decrease mostly due to foreign exchange differences and lower solar radiation in EMEA.Cash available for distribution (“CAFD”) increased by 5.4% year-over-year up to $47.6 million in the first quarter of 2020.Quarterly dividend of $0.41 per share declared by the Board of Directors.No material impact from Covid-19 situation as of today.Refinanced part of the solar assets in Spain with a Green Project Finance, unlocking approximately a $143 million “recap” expected to be used for new investments in renewable assets.Creation of a Renewable Energy Growth Platform with financial partners in Chile.May...

Continue reading

trivago N.V.’s First Quarter 2020 Earnings Release Scheduled for May 18, 2020; Webcast Scheduled for May 19, 2020

DÜSSELDORF, GERMANY – May 7, 2020 – trivago N.V. (NASDAQ: TRVG) announced today that it will release its financial results for the first quarter for the period ended March 31, 2020 on Monday, May 18, 2020 after market close. On the next day, Tuesday, May 19, 2020, trivago N.V.’s management will conduct a webcast beginning at 2:15 PM CEST / 8:15 AM EDT. These items will be available in the Investor Relations section of the company’s website at https://ir.trivago.com/. A replay of the call is expected to be available for at least three months.About trivago N.V.trivago N.V. (NASDAQ: TRVG) is a global hotel search platform. We are focused on reshaping the way travelers search for and compare hotels, while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers via our websites...

Continue reading

TearLab Corporation Confirms Merger Discussions

ESCONDIDO, Calif., May 07, 2020 (GLOBE NEWSWIRE) — In light of recent market rumors, TearLab Corporation (OTCQB: TEAR) (“TearLab”) today confirmed that TearLab is engaged in advanced discussions regarding a potential business combination whereby TearLab will be acquired at a price per share equal to $0.0586. Any transaction would be subject to the approval of TearLab’s board of directors and stockholders, as well as other customary conditions contained in a definitive agreement.TearLab cautioned that no agreement has been reached. TearLab also noted that there cannot be any assurance that an agreement will be reached or, if an agreement is reached, that a transaction will be completed. Accordingly, prior to making investment decisions, investors should take into consideration all publicly available information about TearLab, including...

Continue reading

Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference

ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tuesday, May 12, 2020, at 9:00 a.m. Eastern Time.A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replay of the webcast will be archived on the Company’s website for 90 days following the event.Esperion TherapeuticsThrough scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing...

Continue reading

electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

BASKING RIDGE, N.J., May 07, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of the market on Thursday, May 14, 2020.  Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.For...

Continue reading

Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients

Nes Ziona, Israel, May 07, 2020 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of AllocetraTM (formerly referred to as off-the-shelf AllocetraTM) in COVID-19 patients has commenced.“While work investigating the exact pathophysiology of COVID-19 is ongoing, recent publications have described the complications related to the virally induced COVID-19 disease as associated with organ dysfunction and cytokine storms, which are markedly similar to those observed in septic patients in the ICU,” said Prof. Vernon van Heerden, Head of the Critical Care Medicine Unit at Hadassah Hospital in Israel, and the lead investigator of both the COVID-19 trial and a recently-completed Phase Ib clinical trial of AllocetraTM...

Continue reading

TORM plc to announce first quarter 2020 results

TORM plc (“TORM” or the “Company”) (ticker: TRMD A on Nasdaq in Copenhagen and TRMD on Nasdaq in New York) will release its financial results for the first quarter of 2020 on Thursday, 14 May 2020.The Company’s results will be presented at a conference call at 9:00 am Eastern Time / 3:00 pm Central European Time. If you wish to participate in the call, please dial +45 3272 0417 (or +1 (646) 741 3167 for US connections) at least ten minutes prior to the start of the call to ensure connection and use 2797502 as conference ID.There will be a simultaneous live webcast via TORM’s website https://investors.torm.com. Participants should register on the website approximately ten minutes prior to the start of the webcast. ABOUT TORMTORM is one of the world’s leading carriers of refined oil products. The Company operates a fleet of approximately...

Continue reading

TORM plc offentliggør regnskabet for første kvartal 2020

Torsdag den 14. maj 2020 offentliggør TORM plc (“TORM” eller “Selskabet”) (symbol: TRMD A på Nasdaq i København og TRMD på Nasdaq i New York) regnskabet for første kvartal 2020.Der afholdes en telekonference kl. 9.00 EST / kl. 15.00 dansk tid, hvor Selskabets resultater vil blive gennemgået. Interesserede kan deltage ved at ringe på tlf. +45 3272 0417 (eller +1 (646) 741 3167 fra USA) mindst ti minutter før telekonferencens start for at sikre forbindelse og oplyse følgende kode: 2797502.Konferencen transmitteres som live webcast via TORMs hjemmeside https://investors.torm.com. Deltagere bedes tilmelde sig på hjemmesiden ca. ti minutter før webcastets start. OM TORMTORM er en af verdens førende transportører af raffinerede olieprodukter. Rederiet driver en samlet flåde på ca. 80 moderne skibe med høje krav til sikkerhed, miljøansvar og...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.